<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109239</url>
  </required_header>
  <id_info>
    <org_study_id>AVF2119g</org_study_id>
    <nct_id>NCT00109239</nct_id>
    <nct_alias>NCT00012285</nct_alias>
  </id_info>
  <brief_title>A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer</brief_title>
  <official_title>A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF (Bevacizumab), in Combination With Capecitabine Chemotherapy, in Subjects With Previously Treated Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This Phase III, multicenter, randomized, active-controlled, open-label trial is designed to&#xD;
      evaluate the efficacy, safety, and pharmacokinetics of rhuMAb VEGF when combined with&#xD;
      capecitabine compared with capecitabine alone in subjects with previously treated metastatic&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">September 2002</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhuMAb VEGF (Bevacizumab)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Women &gt;=18 years of age&#xD;
&#xD;
          -  Histologically confirmed carcinoma of the breast with metastatic disease that is&#xD;
             currently progressing; in subjects who present with metastatic disease, cytologic&#xD;
             confirmation is permissible&#xD;
&#xD;
          -  Prior administration of one or two conventional chemotherapy regimens for metastatic&#xD;
             disease (Subjects who have had bone marrow or peripheral blood stem cell&#xD;
             transplantation in association with chemotherapy are eligible for this study.) -OR-&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease if the subject received a regimen&#xD;
             containing both an anthracycline (or anthracenedione) and a taxane as adjuvant therapy&#xD;
             and if relapse occurred within 12 months of completing adjuvant chemotherapy&#xD;
&#xD;
          -  Prior administration of both an anthracycline (or anthracenedione) and a taxane in&#xD;
             either the adjuvant or metastatic setting&#xD;
&#xD;
          -  Recovery from reversible toxicities of prior therapy&#xD;
&#xD;
          -  Bi-dimensionally measurable disease; at least one target lesion must be&#xD;
             bi-dimensionally measurable and at least one target lesion must not have been biopsied&#xD;
             recently; all target lesions must be &gt;=2 cm in longest dimension&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Use of an effective means of contraception in women of childbearing potential&#xD;
&#xD;
          -  Life expectancy of &gt;=3 months&#xD;
&#xD;
          -  Willingness and capability to be accessible for follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pleural effusions or bone lesions as the only manifestations of the current metastatic&#xD;
             breast cancer&#xD;
&#xD;
          -  Known HER2-positive status (either 3+ by immunohistochemistry or positive by FISH), as&#xD;
             evaluated at the institution, unless the subject has previously relapsed following&#xD;
             Herceptin(R) therapy. Subjects may not continue Herceptin therapy while enrolled in&#xD;
             this trial.&#xD;
&#xD;
          -  Other primary malignancies (other than basal cell carcinoma of the skin or in situ&#xD;
             cervical cancer) within the 5 years preceding Day 0&#xD;
&#xD;
          -  Prior radiotherapy to a measurable metastatic lesion(s) if it is to be used as the&#xD;
             only lesion to measure response, unless the target lesion within the radiation field&#xD;
             is actively progressing and radiotherapy was completed &gt;=6 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Radiation therapy, hormonal therapy, biologic therapy, or chemotherapy for metastatic&#xD;
             breast cancer within 21 days prior to Day 0&#xD;
&#xD;
          -  Use of bisphosphonates unless initiated at least 21 days before Day 0&#xD;
&#xD;
          -  Previous treatment with capecitabine&#xD;
&#xD;
          -  Previous treatment with rhuMAb VEGF&#xD;
&#xD;
          -  History or evidence upon physical examination of CNS disease (e.g., primary brain&#xD;
             tumor, seizures not controlled with standard medical therapy, any brain metastases, or&#xD;
             history of stroke; all subjects must have a baseline CT or MRI of the head.)&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (e.g., uncontrolled hypertension,&#xD;
             myocardial infarction, unstable angina), New York Heart Association (NYHA) Grade II or&#xD;
             greater congestive heart failure, serious cardiac arrhythmia requiring medication, or&#xD;
             Grade II or greater peripheral vascular disease within 1 year prior to Day 0&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to Day 0, or anticipation of need for major surgical procedure during the course&#xD;
             of the study; fine needle aspirations other than in the breast within 7 days prior to&#xD;
             Day 0; placement of a vascular access device within 7 days prior to Day 0&#xD;
&#xD;
               -  Current or recent (within 10 days prior to Day 0) use of full-dose oral or&#xD;
                  parenteral anticoagulants or thrombolytic agents (except as required to maintain&#xD;
                  patency of preexisting, permanent indwelling IV catheters; for subjects receiving&#xD;
                  warfarin, international normalized ratio [INR] of &lt;1.5; appropriate use of&#xD;
                  heparin should be discussed with the Medical Monitor)&#xD;
&#xD;
               -  Chronic, daily treatment with aspirin (&gt;325 mg/day) or nonsteroidal&#xD;
                  anti-inflammatory medications (of the kind known to inhibit platelet function at&#xD;
                  doses used to treat chronic inflammatory diseases)&#xD;
&#xD;
          -  Presence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Active infection requiring parenteral antibiotics on Day 0&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test) or lactation&#xD;
&#xD;
               -  Proteinuria at baseline or clinically significant impairment of renal function&#xD;
&#xD;
          -  Severe renal impairment (creatinine clearance &lt;30 mL/min at baseline using the&#xD;
             Cockcroft-Gault formula)&#xD;
&#xD;
          -  Known sensitivity to 5-FU&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract, known malabsorption or&#xD;
             other significant disease of the stomach, small intestine, liver, or kidney that may&#xD;
             adversely affect the pharmacokinetics of capecitabine&#xD;
&#xD;
          -  History of allergy to iodine-containing contrast that required treatment and that&#xD;
             would prohibit use of CT scan with contrast&#xD;
&#xD;
          -  Screening clinical laboratory values: *ANC of &lt;1500/uL; *Platelet count of &lt;75,000/uL;&#xD;
             *INR of &gt;=1.5; *Total bilirubin of &gt;1.5 times upper limit of normal; *AST or ALT &gt;2.5&#xD;
             times the upper limit of normal (&gt;5 times the upper limit of normal in subjects with&#xD;
             known metastatic disease in the liver); *Serum creatinine of &gt;2.0 mg/dL; *Hemoglobin&#xD;
             of &lt;9 gm/dL (may be transfused to maintain or exceed this level)&#xD;
&#xD;
          -  History of other disease, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that might affect the&#xD;
             interpretation of the results of the study or render the subject at high risk from&#xD;
             treatment complications&#xD;
&#xD;
          -  Current or recent (within 28 days prior to Day 0) participation in another&#xD;
             experimental drug study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 26, 2005</study_first_submitted>
  <study_first_submitted_qc>April 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2005</study_first_posted>
  <last_update_submitted>June 16, 2014</last_update_submitted>
  <last_update_submitted_qc>June 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

